TW202313684A - 抗ｃｃｒ８抗體及其用途 - Google Patents

抗ｃｃｒ８抗體及其用途 Download PDF

Info

Publication number
TW202313684A
TW202313684A TW111120681A TW111120681A TW202313684A TW 202313684 A TW202313684 A TW 202313684A TW 111120681 A TW111120681 A TW 111120681A TW 111120681 A TW111120681 A TW 111120681A TW 202313684 A TW202313684 A TW 202313684A
Authority
TW
Taiwan
Prior art keywords
seq
antibody
amino acid
acid sequence
ccr8
Prior art date
Application number
TW111120681A
Other languages
English (en)
Chinese (zh)
Inventor
納森 威廉 皮爾斯
陳文濤
安格尼絲卡 凱爾瑞斯卡
史提沃斯 奧利維爾 諾蘭
達倫 Ｌ 貝茲
麗紗 溫可
克里斯多福 戴爾哈福
托拜耳斯 瑞烏
克勞蒂亞 布魯梅爾
喬納斯 卡爾 喬瑟夫 奧諾
Original Assignee
美商安進公司
德商安美基研究（慕尼黑）公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安進公司, 德商安美基研究（慕尼黑）公司 filed Critical 美商安進公司
Publication of TW202313684A publication Critical patent/TW202313684A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW111120681A 2021-06-04 2022-06-02 抗ｃｃｒ８抗體及其用途 TW202313684A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163197271P 2021-06-04 2021-06-04
US63/197,271 2021-06-04
US202163236551P 2021-08-24 2021-08-24
US63/236,551 2021-08-24

Publications (1)

Publication Number Publication Date
TW202313684A true TW202313684A (zh) 2023-04-01

Family

ID=82358418

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111120681A TW202313684A (zh) 2021-06-04 2022-06-02 抗ｃｃｒ８抗體及其用途

Country Status (17)

Country Link
US (2) US12258411B2 (enExample)
EP (1) EP4347655A1 (enExample)
JP (1) JP2024522360A (enExample)
KR (1) KR20240017912A (enExample)
AU (1) AU2022285741A1 (enExample)
BR (1) BR112023025433A2 (enExample)
CA (1) CA3222764A1 (enExample)
CL (2) CL2023003607A1 (enExample)
CO (1) CO2023018064A2 (enExample)
CR (1) CR20230581A (enExample)
IL (1) IL308808A (enExample)
JO (1) JOP20230312A1 (enExample)
MX (1) MX2023014458A (enExample)
PE (1) PE20240363A1 (enExample)
TW (1) TW202313684A (enExample)
UY (1) UY39798A (enExample)
WO (1) WO2022256563A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308808A (en) * 2021-06-04 2024-01-01 Amgen Inc Antibodies against CCR8 and their uses
WO2024097741A1 (en) * 2022-11-04 2024-05-10 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
AR131785A1 (es) 2023-02-06 2025-04-30 Bayer Ag Combinaciones de inhibidores de dgk (diacilglicerol quinasa)
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ｃｃｒ８を抗原として認識する二重特異性抗体
AU2024305430A1 (en) * 2023-06-12 2026-01-22 Nanjing Probio Biotech Co., Ltd. Antibody binding to human ccr8 and the use thereof
AU2024354737A1 (en) 2023-10-06 2026-04-16 Amgen Inc. Combination therapy for cancer treatment
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20260056209A1 (en) 2024-06-14 2026-02-26 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
CN104497143B (zh) 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
DK2771364T3 (da) 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016176504A1 (en) * 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
ES2863412T3 (es) 2017-03-29 2021-10-11 Shionogi & Co Composición farmacéutica para el tratamiento del cáncer
JP2019122373A (ja) 2018-01-12 2019-07-25 アムジエン・インコーポレーテツド 抗ｐｄ−１抗体及び治療方法
CN110835371A (zh) 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8单克隆抗体及其应用
KR102940634B1 (ko) * 2018-12-27 2026-03-17 시오노기세이야쿠가부시키가이샤 신규 항 ccr8 항체
TWI906906B (zh) * 2020-01-06 2025-12-01 美商法西尼克斯股份有限公司 抗ccr8抗體及其用途
CN117964757A (zh) 2020-02-14 2024-05-03 吉利德科学公司 与ccr8结合的抗体和融合蛋白及其用途
CN115768792A (zh) 2020-03-23 2023-03-07 百时美施贵宝公司 抗ccr8抗体用于治疗癌症
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
EP4173636A4 (en) 2020-06-30 2024-08-28 Shionogi & Co., Ltd Combined use of anti-ccr8 antibody and chemotherapeutic agent
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
JP2023538897A (ja) 2020-08-20 2023-09-12 アムジエン・インコーポレーテツド Ｆａｂ領域中に非標準的なジスルフィドを有する抗原結合タンパク質
CN117098561A (zh) 2020-08-28 2023-11-21 和铂医药美国股份有限公司 Ccr8抗体及其应用
WO2022081718A1 (en) * 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
CA3198647A1 (en) 2020-10-16 2022-04-21 LaNova Medicines Limited Anti-ccr8 monoclonal antibodies and uses thereof
EP4267621A1 (en) 2020-12-24 2023-11-01 Vib Vzw Murine cross-reactive human ccr8 binders
EP4267617A1 (en) 2020-12-24 2023-11-01 Vib Vzw Human ccr8 binders
US20240052044A1 (en) 2020-12-24 2024-02-15 Vib Vzw Non-blocking human ccr8 binders
AU2022287014A1 (en) * 2021-06-04 2023-12-07 Amgen Inc. T cell engager molecules and uses thereof
IL308808A (en) * 2021-06-04 2024-01-01 Amgen Inc Antibodies against CCR8 and their uses

Also Published As

Publication number Publication date
JP2024522360A (ja) 2024-06-18
KR20240017912A (ko) 2024-02-08
US12258411B2 (en) 2025-03-25
AU2022285741A1 (en) 2023-12-14
CO2023018064A2 (es) 2024-01-15
IL308808A (en) 2024-01-01
JOP20230312A1 (ar) 2023-11-29
US20250171549A1 (en) 2025-05-29
EP4347655A1 (en) 2024-04-10
MX2023014458A (es) 2023-12-15
BR112023025433A2 (pt) 2024-02-27
CR20230581A (es) 2024-02-13
WO2022256563A1 (en) 2022-12-08
CL2023003607A1 (es) 2024-06-07
PE20240363A1 (es) 2024-03-04
UY39798A (es) 2022-12-30
CA3222764A1 (en) 2022-12-08
CL2024003552A1 (es) 2025-08-01
US20220403037A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
KR20240017912A (ko) 항-ccr8 항체 및 이의 용도
AU2022201144B2 (en) Antigen binding molecules comprising a TNF family ligand trimer
TWI811982B (zh) 對共刺激tnf受體具特異性之雙特異性抗體
KR102665542B1 (ko) T 세포 활성화 이중특이적 항원 결합 분자 CD3 ABD 엽산 수용체 1(FolR1) 및 PD-1 축 결합 길항물질의 조합 요법
AU2021254602A1 (en) Humanized anti-MUC1* antibodies
TWI363762B (en) Antibodies to madcam
CN110573528B (zh) 针对共刺激性tnf受体的双特异性抗原结合分子
CN110382542B (zh) 针对共刺激性tnf受体的双特异性抗原结合分子
KR20200014414A (ko) Pd-1과 특이적으로 결합하는 항체 및 사용 방법
KR20180099723A (ko) 항-tl1a/항-tnf-알파 이중특이적 항원 결합 단백질 및 그의 용도
AU2016334623A1 (en) Bispecific antibodies with tetravalency for a costimulatory TNF receptor
KR20230041819A (ko) Hla-g 항원-결합 도메인을 포함하는 단백질 및 이의 용도
KR20150122203A (ko) T 세포 활성화 이중특이적 항원 결합 분자
KR20230017841A (ko) Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
CN111032694B (zh) 针对madcam的抗体
KR20220117300A (ko) 고형 종양의 치료를 위한 메소텔린-표적화 cd40 작용성 다중특이성 항체 작제물
HK40086038A (zh) 对共刺激性tnf受体特异性的双特异性抗体
EA044746B1 (ru) АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ ПРОТИВ ГЛИКОПРОТЕИНА ШИПОВ SARS-CoV-2
HK40015870A (en) Bispecific antigen binding molecule for a costimulatory tnf receptor
HK40019153B (en) Bispecific antigen binding molecule for a costimulatory tnf receptor
HK40061781A (en) Antigen binding molecules comprising a tnf family ligand trimer
HK40015870B (en) Bispecific antigen binding molecule for a costimulatory tnf receptor
HK40019153A (en) Bispecific antigen binding molecule for a costimulatory tnf receptor
HK1261508A1 (en) Bispecific antibodies specific for a costimulatory tnf receptor
HK1261508B (en) Bispecific antibodies specific for a costimulatory tnf receptor